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Abstract
Background/Aim: Since hyperandrogenism in simple
obesity is assumed to arise from hyperinsulinism and/or
increased insulin-like growth factor I (IGF-I) or leptin lev-
els, we examined how in patients with Prader-Willi syn-
drome (PWS), the most frequent form of syndromal obe-
sity, the accelerated adrenarche can be explained de-
spite hypothalamic-pituitary insufficiency with low levels
of insulin and IGF-I. Methods: In 23 children with PWS
and a mean age of 5.6 years, height, weight, fat mass,
fasting insulin concentration, insulin resistance (by
HOMA-R; see text), and leptin and IGF-I levels were
determined to test whether they explain the variance of
the levels of dehydroepiandrosterone (DHEA) and its sul-
fate (DHEAS), of androstenedione, and of cortisol before
and during 42 months of therapy with growth hormone.
Results: The baseline DHEAS, DHEA, and androstene-
dione concentrations were increased as compared with
age-related reference values, whereas the cortisol level
was always normal. During growth hormone treatment,
the DHEA concentration further rose, and the cortisol lev-
el decreased significantly. The insulin and IGF-I concen-
trations were low before therapy, while fat mass and lep-
tin level were elevated. The hormonal covariates pro-
vided alone or together between 24 and 60% of the
explanation for the variance of adrenal androgen levels,
but the anthropometric variables did not correlate with
them. Conclusions: In children with PWS, elevated an-
drogen levels correlate with hormones that are usually
associated with adiposity. However, the lack of direct
correlations between disturbed body composition and
androgen levels as well as the increased sensitivity to
insulin and IGF-I are abnormalities specific to PWS,
potentially caused by the underlying hypothalamic de-
fect.
Copyright © 2002 S. Karger AG, Basel
Introduction
Childhood obesity is generally accompanied by accel-
erated growth [1] and early sexual development. A recent
study conducted in 17,077 US girls confirmed that higher
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body mass index (BMI) z-scores were found in white girls
with isolated pubic hair growth [2]. Early pubarche can
result from a precocious increase of adrenal androgen lev-
els present in obesity [3–5]. Adrenal stimulation, in turn,
may be the consequence of hyperinsulinism and/or in-
creased bioavailability of insulin-like growth factor I
(IGF-I) [6–8]. In addition, leptin is reported to increase
the adrenal activity in prepubertal children, e.g., via stim-
ulation of corticotropin-releasing hormone [9], and leptin
also stimulates the synthesis of adrenal androgens in vitro
[10].
Prader-Willi syndrome (PWS) is the most frequent
form of syndromal obesity. The phenotype is linked with
a hypothalamic defect. To date, growth hormone (GH)
insufficiency and hypogonadism are well described, and
the gonadal development at puberty is typically delayed
or incomplete. Surprisingly, in this context, premature
adrenarche may be observed in children affected by PWS
[11–15], although the insulin [16] and IGF-I [17] levels
are below the normal average due to insufficient GH
secretion [18]. The issue of accelerated adrenal develop-
ment against a background of hypothalamic-pituitary in-
sufficiency in PWS has not yet been explained. Although
gross abnormalities of adrenal function have not been
reported, the integrity of the hypothalamic-pituitary-
adrenal axis needs to be confirmed by yet more sophisti-
cated methods [19, 20]. Therefore, it has not yet been
specified, whether premature adrenarche is the conse-
quence of an underlying hypothalamic dysfunction or
results from adiposity, as in healthy obese children [3, 4].
In order to test the hypothesis that premature adren-
arche in PWS is caused by obesity and related metabolic
alterations, independently of the hypothalamic regula-
tion, we studied the relations between adrenal androgens
and body composition parameters or associated hor-
mones, such as insulin, IGF-I, and leptin, in children with
PWS and the potential changes induced by treatment with
GH. The cortisol levels were documented to assess altera-
tions of the adrenal glucocorticoid axis.
Patients and Methods
In a prospective study, we examined a group of 23 children, 11
girls and 12 boys, with genetically proven PWS, in whom growth and
body composition before and during long-term GH therapy (GHT)
were previously described [21, 22]. At baseline, the mean age was 5.6
(range 0.5–14.6) years and the bone age 6.15 (range 0.6–14.6) years.
Four girls and 1 boy had entered puberty at onset of therapy (breast
stage 2–3 and genital stage 3, respectively). The observation period in
19 children (8 female, 11 male) was long enough to notice precocious
pubic hair development during the critical age, but 4 adolescents
were presented after the age of 9 years, thus too late to observe preco-
cious pubarche. Premature adrenarche was defined as precocious
pubic hair growth before the age of 8 years in girls and of 9 years in
boys and elevated adrenal androgen levels. The following parameters
were assessed at baseline as well as during 12 and 42 months of thera-
py with 8 mg/m2/week (F0.037 mg/kg/day) recombinant GH (Phar-
macia, Dübendorf, Switzerland), administered by daily subcuta-
neous injections. The fat mass was measured by dual-energy X-ray
absorptiometry [22], pubertal stage, height, and weight by standard
techniques [23], serum glucose by the standard hexokinase method,
fasting insulin by enzyme-linked immunoabsorbent assay (Tosoh,
Tokyo, Japan) and, since 1997, by ‘Access ultrasensitive’ sandwich
immunoassay [Beckmann, Zürich, Switzerland; interassay coeffi-
cient of variation (CV) = 3.5%], cortisol by chemiluminescence assay
(Nichols Institute, Nijmegen, The Netherlands; CV = 7.1%),
androstenedione (AD) by 125I-RIA (DSL, Webster, Tex., USA; CV =
4.8%), dehydroepiandrosterone (DHEA) also by 125I-RIA (DSL;
CV = 3.5%) and its sulfate (DHEAS) by chemiluminescence assay
(Nichols Institute; CV = 9.0%), and leptin (CV = 8.5%) [24] and IGF-
I (CV = 10.1%) [25, 26] as published by the authors. Data for subjects
with PWS were judged individually as to whether they were within
the age- and sex-related reference range used by the laboratory mea-
suring the respective parameter. Examples of reference ranges for
boys and girls together, age 6–9 years are given in table 1 and 2 to
facilitate the estimation of mean values in patients with PWS. In par-
ticular, reference data for androgens and cortisol in US children were
provided by Endocrine Sciences (Tarzana, Calif., USA). We recently
described [22] how lean and fat mass were related to normative data
established in Caucasian US [27] and in Dutch children [28, 29]. The
leptin concentration as well as the BMI (body weight in kilograms
divided by the square of height in meters) were compared with age-
related data of healthy German schoolchildren, while IGF-I [25] and
Insulin [30] levels were compared with data obtained from Swiss and
Finnish children, respectively, as published previously [17]. The
insulin resistance was assessed by homeostasis model analysis
(HOMA-R) and compared with data of healthy adults [31]. Missing
values were not due to a specific selection of patients or dropouts, but
to shortage of serum as a result of the difficulties encountered during
venipuncture in children with PWS or, in 3 patients, to uncompleted
investigation intervals as a consequence of delayed start of therapy.
For the same reason, the AD levels before therapy could not be
included into the evaluation.
The patients continued their energy-reduced diets during the
study protocol [21, 22]. No additional medication was administered
besides substitution for hypothyroidism in 1 1.5-year-old boy (L-
tyroxine 50 Ìg) and for hypogonadism in 3 adolescents after more
than 14 months of GHT: 1 14.5-year-old girl receiving ethynyl estra-
diol 10 Ìg, 1 14.8-year-old boy treated with testosterone enanthate
100 mg i.m., and 1 16.6-year-old girl receiving Trisequens® (2 mg
estradiol, 1 mg norethisterone acetate) [21, 22].
The study has been approved by the Ethics Committee of the
Children’s University Hospital of Zürich, and informed consent was
obtained from the parents.
Statistical Methods
All data were processed by GAS 4.1 of the Institute for Medical
Informatics (IMI, Zürich, Switzerland). Because most of the vari-
ables showed a skewed distribution, they were transformed to loga-
rithms which resulted in an approximately normal distribution. We
had to establish age-standardized values, since all variables, except
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Table 1. Adrenal serum steroids in children with PWS (dependent variables, mean B SEM)
Reference range
(6- to 9-year-old
females and males)a
Before
therapy
n 12 months
after GHT
n 42 months
after GHT
n
DHEAS, nmol/l !1,460 1,630B500 19 2,410B610n.s. 19 3,340B710n.s. 14
DHEA, nmol/l 0.7–9.1 10.2B2.9 17 19.6B4.5(#) 19 22.2B3.5# 15
AD, nmol/l 0.3–1.7 (3.3B0.83) 6 2.38B0.5 18 3.3B0.53 15
Cortisol, nmol/l 240–690 440B53 16 260B30### 18 270B20## 17
a See Patients and Methods for further description of reference data (provided by the Institute of Pediatric Endocri-
nology, Basel, Switzerland).
b Between 12 and 42 months of GHT, no significant change of any parameter was found.
(#), #, ##, ###, n.s. p = 0.06, !0.05, !0.01, !0.001, or not significant, respectively, indicate whether the residuals of the
hormones at 12 or 42 months, corrected for age at baseline, differ significantly from data before therapy (tested by
paired t test).
Table 2. Hormonal and anthropometric covariates in children with PWS (mean B SEM)
Reference range
(6- to 9-year-old
females and males)a
Before
therapy
n 12 months
after GHT
n 42 months
after GHT
n
BMI, kg/m2 16.55B2.07 [24] 19.1B1.2 23 18.7B1.4### 23 18.7B0.93### 19
Fat, kgb 5.89B4.3 [27, 29] 13.1B3.25 16 12.5B4.0# 16 11.6B2.0# 13
IGF-I, ng/ml 161B61 [25, 26] 101B15 23 287B30### 22 375B38### 17
Leptin, ng/ml 2.51B1.16 [24] 13.4B3.4 23 10.1B4.0### 12 –
Insulin, mU/l 7.10B3.70 [30] 6.18B1.84 18 9.26B1.40## 19 5.13B1.00#, † 16
HOMA-Rc 1.48B0.46 [31] 1.30B0.39 15 1.99B0.33# 13 1.12B0.17n.s, d 14
For definition of the significance levels see table 1.
a See Patients and Methods for further description of reference data.
b Data of body composition shown in detail elsewhere [22].
c Index of insulin resistance = Ins [mU/L] / 22.5*e–lnGluc[mmol/l].
d Data obtained after 36 months of GHT.
† Significance of differences of the residuals at 42 months, corrected for age at baseline, vs. data at 12 months
(tested by paired t test).
for cortisol, were clearly age dependent. To do so, we calculated a
least squares fit with age as explanatory variable and the logarithm of
the variable as the response. This regression was made independently
at baseline and at 12 and 42 months of GH treatment. Age-standard-
ized values were then defined as the residuals with respect to each fit.
This standardization technique is equivalent to considering age as a
covariate. Such standardized variables will be denoted by the sub-
script ‘res’ in the following sections of the paper.
For each variable, we also compared values at baseline with val-
ues after 12 or 42 months of GHT. In order to distinguish whether
the changes observed were solely related to the increase of age or
whether they were due to the particular effect of GHT, we calculated
age-standardized values after 12 or 24 months of GHT with respect
to the baseline regression equation. In doing so, we were able to elim-
inate the age effect from all variables. We then applied paired t tests
to assess any significant difference between baseline residuals versus
residuals after 12 or 42 months, all being age-standardized by the
same baseline equation, hence indicating changes due to the treat-
ment itself. Note that, after 12 or 42 months of GHT, this estimate
included the extrapolation of age for the adolescents older than the
maximal age of 14.6 years at start. But we obtained essentially the
same results by repeating the same calculations without the extrapo-
lated values.
To allow for a sufficient number of subjects being available for
statistical calculations, we decided to evaluate data of girls and boys
together, because initial pubertal stages of pubic hair, breast, and
genitalia were below 3 and because graphical representations did not
reveal an obvious gender difference.
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In order to investigate the relative contribution of anthropomet-
ric (BMIres and fat massres) and hormonal variables (leptinres, IGF-
Ires, fasting insulinres, or HOMA-Rres) to the levels of DHEASres,
DHEAres, ADres (this only after 12 and 42 months ), and cortisolres, we
considered regression models with one or two explanatory variables.
The relationship between an ‘explanatory’ – anthropometric or hor-
monal – variable and the response (DHEASres, DHEAres or corti-
solres) was characterized by the Pearson correlation coefficient rPea or,
equivalently, by its square, R2, expressed as a percentage which
represents the proportion of the response due to the explanatory vari-
able. The relationship between two explanatory variables was inves-
tigated in the same way. In the regression models with two explanato-
ry variables, we used F tests to assess the joint influence and partial F
tests to assess the contribution of each explanatory variable intro-
duced into the model.
Throughout the analyses, p ! 0.05 was considered significant,
whereas we considered to have a trend for p values between 0.05 and
0.10.
Results
Premature adrenarche was observed in 1 girl out of 19
patients (5.2%) before and in 1 girl and 1 boy (10.5%)
during GHT. Excluding young children below the age of 3
years, in whom the presentation of idiopathic premature
adrenarche is highly improbable, the incidence would rise
to 1 of 11 (9.1%) children before and to 2 of 11 (18.2%)
children during therapy. High androgen levels, e.g., values
exceeding the normal range for gender and age, were
found in 47% of the DHEAS and in 35% of the DHEA
samples at baseline. This proportion increased after 1
year of GHT to 53 and 63%, respectively; after 3.5 years
of GHT, again 53% of the children presented with ele-
vated DHEAS levels and 72% with elevated DHEA levels
(data not shown).
Along this line, the mean levels of DHEAS, DHEA,
and AD were higher than our reference ranges at the base-
line examination and even more distinctively so after 12
and 42 months of GHT (table 1). However, when the
changes of variables were corrected for the effect of age,
only the increase of DHEA was significant after 42
months. In fact, the observed increase of DHEAS was due
to age. For AD we lacked a sufficient number of measure-
ments before therapy to draw any conclusion. Thus, on
average, the increase of adrenal androgens in the group
was not clearly associated with the institution of GH
treatment. In contrast, the cortisol levels were well within
the normal range at the first examination and significant-
ly dropped to the lower normal range during GHT.
The covariates showed several abnormalities, as dem-
onstrated in previous studies [17, 22, 32]. Mainly the fat
mass was increased in PWS, and the leptin levels and the
BMI were high (table 2, as a consequence of their strong
correlation with fat mass (r = 0.85 and r = 0.75, respec-
tively, with both p ! 0.01 and n = 16). In spite of adiposi-
ty, IGF-I, fasting insulin, and insulin resistance (HOMA-
R) were in the lower normal range, being explained by
hypothalamic GH deficiency, before therapy. During the
GHT, the increase in IGF-I levels was highly significant,
and a significant loss of fat mass was induced, accompa-
nied by a significant decrease of leptin and BMI, all vari-
ables having been corrected for age as described in
Patients and Methods. The insulin levels significantly
rose after 1 year of GHT to fall slightly below baseline
levels after 42 months.
Before therapy, significant positive correlations were
found between the adrenal androgens DHEAS and
DHEA as well as several hormonal parameters, but not
with anthropometric variables (table 3).
In the regression models, R2 was deduced from correla-
tion coefficients (table 3) as indicated in Patients and
Methods, and first DHEAS as dependant variable was
investigated. 34% of the DHEAS variance was explained
by insulin alone, and the bivariate model, when insulin
was already in, remained significant, but substantially
unchanged by the introduction of BMI or IGF-I (38 or
39% of DHEAS variance explained, respectively; p !
0.05, n = 16). Therefore, insulin, but not IGF-I, had the
main influence on DHEAS in this model. The surrogate of
insulin resistance, HOMA-R, was even more strongly
linked with DHEAS: HOMA-R alone explained 42% of
the DHEAS variability in the univariate model deduced
from rPea (table 3), and this relationship remained similar
in the bivariate models additionally including IGF-I (R2 =
44%, p = 0.055, n = 13), fat mass (R2 = 50%, p = 0.043, n =
12), or BMI (data not shown), all by themselves not being
significantly associated with DHEAS (table 3). The co-
variate insulin was not significantly related to fat mass or
body mass, and there was only a trend of HOMA-R to
correlate with fat mass or BMI (r = 0.5 for both; p = 0.068
and n = 14 and p = 0.056 and n = 15, respectively).
Because of the small sample, there was only a trend,
although the correlations were substantial. Leptin or
IGF-I levels were not associated with DHEAS, neither
alone (table 3) nor in any combination tested (data not
shown).
In the univariate model with DHEA, 24% of the vari-
ance of the androgen was explained by leptin alone, but in
the bivariate model neither the introduction of BMI (not
significant) nor of fat mass (36%, p = 0.087, n = 14) signif-
icantly increased R2, both covariates alone not being sig-
nificantly associated with DHEA (table 3). Furthermore,
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Table 3. Correlations in children and adolescents with PWS before therapy
0 months DHEASres
r p n
DHEAres
r p n
Cortisolres
r p n
BMIres 0.00 n.s. 19 0.33 n.s. 17 –0.39 n.s. 16
Fat massres 0.00 n.s. 14 0.22 n.s. 14 –0.40 n.s. 14
IGF-Ires 0.22 n.s. 19 0.58 0.016 17 –0.30 n.s. 16
Leptinres 0.20 n.s. 19 0.49 0.046 17 –0.33 n.s. 16
Insulinres 0.58 0.017 16 0.41 0.065 17 –0.28 n.s. 16
HOMA-Rres 0.65 0.018 13 0.57 0.045 13 –0.32 n.s. 13
r = Pearson’s correlation coefficient; p = associated significance; n = sample size available for the analysis of
correlation.
n.s. = Not significant.
Table 4. Correlations after 12 months of GHT
12 months DHEASres
r p n
DHEAres
r p n
ADres
r p n
Cortisolres
r p n
BMIres –0.10 n.s. 19 0.14 n.s. 19 0.00 n.s. 18 –0.22 n.s. 18
Fat massres –0.10 n.s. 14 0.14 n.s. 14 0.27 n.s. 14 –0.48 0.082 14
IGF-Ires 0.30 n.s. 18 0.10 n.s. 18 0.51 0.036 17 –0.10 n.s. 17
Leptinres 0.20 n.s. 10 0.82 0.004 10 0.52 0.15 9 0.28 n.s. 9
Insulinres 0.10 n.s. 16 0.00 n.s. 16 0.00 n.s. 15 –0.40 n.s. 15
HOMA-Rres 0.10 n.s. 10 0.14 n.s. 11 0.00 n.s. 10 –0.23 n.s. 10
r = Pearson’s correlation coefficient; p = associated significance; n = sample size available for the analysis of correlation.
n.s. = Not significant.
the introduction of IGF-I into the bivariate model with
leptin slightly improved the relationship, explaining 40%
of the variance of DHEA (p = 0.03, n = 17). In the next
model, IGF-I, on its own, significantly predicted 33% of
the DHEA variability (table 3). IGF-I with BMI together
accounted for 35% of the DHEA variance (p = 0.051, n =
17). The most significant and additive bivariate model
was found when HOMA-R was included in addition to
IGF-I, now explaining together 60% of the DHEA vari-
ance (p = 0.01, n = 13). HOMA-R alone accounted for
32% of the DHEA variance, and this relationship was not
significantly improved neither in conjunction with BMI
nor with fat mass. Insulin was not strongly correlated with
DHEA (table 3, R2 = 22%), but the joint influence of insu-
lin and IGF-I was significant and additive, accounting for
57% of the variance of DHEA (p = 0.004, n = 17). No
significant correlations were found between cortisol and
body composition or hormonal variables before or during
therapy (table 3, 4).
After 12 months of GH treatment (table 4), the levels
of DHEAS were no longer associated with any indepen-
dent variable. The levels of DHEA were now only ex-
plained by leptin (table 4, R2 = 67%), and the regression
model remained roughly unchanged after the addition of
BMI (R2 = 74%, p = 0.008, n = 10) or insulin (R2 = 78%,
p = 0.011, n = 9), but in the bivariate model no other
anthropometric or hormonal parameter was significantly
associated with DHEA. Since at this time the number of
AD measurements was sufficient, the regression model
could also be tested for this dependant variable: IGF-I
was the only parameter to explain the variance of AD (ta-
ble 4, R2 = 26%), and the bivariate model was no longer
significant when other variables were brought in. In this
connection, it has to be pointed out that in children with
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PWS, the covariate IGF-I did not correlate either with
lean mass or with fat mass or BMI before or during thera-
py. Furthermore, the lean mass did not correlate with
adrenal androgens at any time. The development of the
cortisol levels could not be explained by any independent
variable, but there was only a trend for fat mass to be neg-
atively associated with the cortisol levels (table 4).
After 42 months of therapy, no significant explanation
was delivered by the independent variables to interpret
the development of the levels of androgens (data not
shown).
Discussion
In summary, the mean adrenal androgen levels in
patients with PWS are elevated above the normal range,
as described in healthy obese children [3, 4]. The in-
creased levels of DHEAS, DHEA, and AD may give rise
to a precocious growth of pubic hair which then is termed
premature adrenarche [33]. The present study presents
arguments to support the hypothesis that the dissociation
of the adrenal androgen secretion from gonadal matura-
tion in PWS is amplified by obesity and related metabolic
alterations, independently of the hypothalamic regula-
tion.
The increase of adrenal androgen levels in PWS, before
onset of therapy, is correlated with hormones dependent
on body composition and growth, namely insulin, leptin,
and IGF-I. The higher the insulin levels were, and, in par-
ticular, the more insulin-resistant the subject was, the
more the baseline levels of DHEAS and DHEA were
increased. These correlations agree with findings in obese
children with premature adrenarche [34] or in obese hir-
sute women [35]. However, insulin and HOMA-R were in
the lower normal range, in contrast to simple obesity [1,
36]. Since the insulin sensitivity is increased in the pres-
ence of GH insufficiency, it can be deduced that the rela-
tionship to androgens occurs at a lower level of insulin in
patients with PWS. IGF-I is the second important co-
variate related to DHEA at baseline and AD during thera-
py, as in healthy obese children [8, 37] and adolescents
[38]. Most importantly, in the regression models, insulin
or HOMA-R, in addition to IGF-I, make contributions to
explain up to 60% of the variance of baseline DHEA lev-
els. This means that they may represent distinct mecha-
nisms to enhance levels of this androgen. This is corrobo-
rated by in vitro experiments showing that both insulin
[39] and IGFs [40] enhance the enzyme activity of ste-
roidogenic enzymes in human adrenocortical cells.
The data in patients with PWS, showing a correlation
between DHEA and leptin levels, confirm not only find-
ings in healthy children [8], but also experimental results
on the stimulation of androgen formation via 17/20-lyase
at physiological leptin levels in human adrenocortical car-
cinoma cells [10]. An association between increased circu-
lating androgen and leptin levels has so far been observed
only in girls with precocious pubarche [41] and, depen-
dent on BMI, in adult women with polycystic ovary syn-
drome [42]. We suggest that in patients with PWS, as in
healthy subjects, insulin, IGF-I, and leptin mediate the
effects of increasing adiposity to enhance the adrenal
androgen secretion. In fact, longitudinal studies per-
formed in healthy children or primates have revealed that
changes in BMI or related hormones precede adrenarche
[43] or puberty [44] before steroid hormones are secreted.
Normally, the leptin and IGF-I levels both increase before
puberty and might provide the brain with information on
body composition and size to start pituitary, adrenal, and
gonadal maturation [43, 44].
During GHT, the DHEA concentration significantly
rises, potentially due to the increase of insulin and IGF-I
levels [40]. Therefore, GHT is likely to enhance the risk of
premature adrenarche. However, most associations ob-
served previously disappeared, except for those between
leptin and DHEA or IGF-I and AD. The relationships
observed at baseline may in part be offset during therapy
by the strong, direct effects of exogenous GH on IGF-I
concentrations, insulin resistance, and insulin levels [32].
Although the elevation of androgen levels in children
with PWS is correlated with hormones linked with the
body composition, such as insulin, leptin and IGF-I, no
associations are found between androgen levels and adi-
posity or the anthropometric variables BMI, fat, or lean
mass, either before or during therapy. This observation
contrasts results in healthy children with and without sim-
ple obesity, even if the studies were carried out by similar
methods [8]. In healthy children, the pubic hair growth is
advanced with increased BMI [45], and the serum
DHEAS levels are correlated with the BMI [37, 38]. Fur-
thermore, the steroid excretion is increased in obese chil-
dren [46], and the androgen excretion correlates with the
lean mass [47]. The dissociation between anthropometric
variables and increased androgen levels in patients with
PWS suggests that the regulation of body mass and body
composition is altered in PWS, as described by other
authors. There is a peculiar, central subcutaneous fat
deposition in patients with PWS [48], but the visceral fat
compartment is relatively reduced [20] as compared with
simple obesity. The reduction of the metabolically active
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visceral fat is specific to PWS and is compatible with the
observations that insulin levels in these patients are low,
even after 3 years of GHT [32], and that the triglyceride
levels are normal [49].
The levels of circulating cortisol are normal, in contrast
to adrenal androgen levels, and do not correlate with any
other covariate, as described in healthy obese children
[50]. Since the cortisol levels were normal and, during GH
treatment, decreased within the reference range, indepen-
dently of the increase of adrenal androgens, we deduced a
grossly normal hypothalamic-pituitary regulation of the
adrenal gland in PWS. However, in theory, the cortisol
metabolism could be enhanced by changes induced dur-
ing GHT, e.g., insulin increase, but the present outpatient
setting did not allow for a collection of 24-hour urine sam-
ples from the handicapped children. The present study
was not designed to examine the hypothalamic-pituitary-
adrenal axis exhaustively. Therefore, its function in PWS
will have to be assessed in further, more sophisticated
studies.
In conclusion, the typically delayed gonadal develop-
ment in PWS may be contrasted by elevated androgen
levels and premature adrenarche. We suggest that these
represent epiphenomena of hormonal changes induced by
adiposity rather than being the consequence of the as-
sumed hypothalamic defect in PWS. However, in PWS,
specific alterations change the pattern of the pubertal
development: (1) the effects of insulin or IGF-I on circu-
lating androgens are exhibited at lower levels than in sub-
jects with intact hypothalamic function; (2) the associa-
tions between anthropometric and hormonal variables
are disrupted, possibly by the basic defect of the regula-
tion of the body composition, and (3) the gonadal devel-
opment may be impeded due to the hypothalamic defect.
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